Introduction#
Eton Pharmaceuticals Inc, a company focused on rare diseases, has announced that it has begun dosing the first patient in a clinical study for its new treatment, ET-700. This treatment is an extended-release formulation of zinc acetate aimed at managing Wilson disease, a condition that leads to copper accumulation in the body.
Clinical Study Details#
The clinical trial is taking place at Aarhus University Hospital in Denmark and involves 36 healthy volunteers. Participants are randomly divided into three groups: one group will receive GALZIN, a known treatment, while the other two groups will receive ET-700 or a placebo. The study aims to assess how effectively these treatments reduce intestinal copper absorption using advanced imaging techniques called positron emission tomography (PET) scans.
Expected Outcomes#
The primary goal of the study is to measure changes in liver copper absorption before and after the treatment. Results from this study are anticipated in the second half of 2026, and if successful, Eton plans to initiate a larger, pivotal clinical study in early 2027.
Company Performance#
Eton Pharmaceuticals is currently valued at $628 million. Despite a recent decline in stock price, the company has seen a 36% increase in shares year-to-date. Eton markets ten products for rare diseases and has four more in late-stage development. Analysts are optimistic about the company's future, with projections suggesting that ET-700 could generate over $100 million in annual sales if approved. Additionally, Eton recently reported a fourth-quarter earnings per share of $0.19, exceeding expectations, although its product sales fell slightly short of forecasts.